Renal denervation in patients with heart failure secondary to Chagas' disease: A pilot randomized controlled trial. Issue 4 (23rd July 2019)

• Record Type: Journal Article
• Authors: Spadaro, André G.; Bocchi, Edimar A.; Souza, Germano E.; Filho, Antonio E.; Mariani, José; Campos, Carlos M.; Lemos, Pedro A.
• Is Part Of: Catheterization and cardiovascular interventions. Volume 94:Issue 4(2019)
• Page Start: 644
• Page End: 650
• Publication Date: 2019-07-23
• Subjects: Chagas cardiomyopathy -- Chagas heart disease -- heart failure -- radiofrequency ablation -- renal denervation; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.28393
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Introduction: Chagas disease is one of the most relevant endemic parasitic diseases in Latin America, affecting approximately 6 million people. Overt Chagas heart disease is an ominous condition, occurring in 20–30% of infected individuals, which has besides the persistent myocarditis a peculiar intracardiac ganglionic neuronal depletion and dysautonomy. This study aims to evaluate the safety and feasibility of renal denervation for patients with advanced symptomatic Chagas cardiomyopathy. Methods: Open‐label prospective pilot study that randomized patients with Chagas heart disease to either renal denervation or conservative treatment (2:1 ratio). The primary endpoint was the incidence of major adverse events at 9 months, defined as a composite of all‐cause death, myocardial infarction, stroke, need for renal artery invasive treatment, or worsening renal function. Results: A total of 17 patients were allocated for renal denervation ( n = 11) or conservative treatment ( n = 6). Included patients had severe symptomatic heart disease, with markedly depressed left ventricular function (average ejection fraction 26.7 ± 4.9%). For patients randomized to renal denervation, the procedure was performed successfully and uneventfully. After 9 months, the primary endpoint occurred in 36.4% of patients in the renal denervation group and 50.0% in the control arm ( p = .6). After 9 months, clinical, laboratory, functional, echocardiographic, and quality of life parameters were similar between groups. Conclusions: This pilot study suggests that renal denervation is safe and feasible in patients with Chagas cardiomyopathy, warranting future studies to better evaluate the clinical efficacy of the interventional strategy in improving the prognosis of this high‐risk population.